Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat · Jun 5

The CEO who loves AI autodidacts — and desperately needs his experts

Bob Bradway bet on AI before almost anyone else in biotech. Now Amgen is reaping the rewards — and wrestling with what it means for its scientists.

Fortune · Jun 3

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · May 31

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Grind Higher on Good Fundamentals: Stock Market Today

The stock market is a forward-looking mechanism, and what it sees at the bottom line carries greater weight right now than geopolitical uncertainty.

Kiplinger · May 27

Why Wall Street Thinks This Dividend Stock Could Jump 30%

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Barchart · May 22

S&P 500 Hits New High on Apple Earnings: Stock Market Today

Apple rounded out a big week of mega-cap earnings on a high note, sending two of the three main equity indexes to new highs on Friday.

Kiplinger · May 1

What to Expect From Amgen's Next Quarterly Earnings Report

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

Barchart · Apr 20

Read news from The Economist, FT, and more,
with one subscription

Dow Leads in Mixed Session on Amgen Earnings: Stock Market Today

The rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.

Kiplinger · Feb 4

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart · Feb 3

Amgen Stock: Is Wall Street Bullish or Bearish?

Are Wall Street analysts bullish or bearish on Amgen’s stock prior to its Q4 earnings release?

Barchart · Feb 2

Dow Hits New High Then Falls 466 Points: Stock Market Today

The Nasdaq Composite, with a little help from tech's friends, rises to within 300 points of its own new all-time high.

Kiplinger · Jan 7

6 Dividend Stocks Retirees Are Quietly Buying for Steady Income

For retirees, dividend stocks can offer the best of both worlds. The most obvious is a steady income stream, one that often increases over time. The other is the potential for capital appreciation,...

GOBankingRates · Dec 18, 2025

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

MarketBeat · Dec 16, 2025

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

Benzinga · Dec 3, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Dec 1, 2025

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat · Nov 7, 2025

Amgen Stock: New All-Time Highs Ahead After Earnings Beat

Amgen stock jumps after a strong beat-and-raise quarter, pushing shares near split-adjusted all-time highs and signaling more upside ahead

International Business Times UK · Nov 6, 2025

Marjorie Taylor Greene Already Made Double-Digit Gains From Amazon; Cardinal Health Trades Days Before Earnings Beat

Greene's investments in Amazon and Cardinal Health on 24 October are up 11.5% and 21.5%, respectively, following the companies' strong Q3 earnings reports.

Barchart · Oct 31, 2025

Amgen Stock: Analyst Estimates & Ratings

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Oct 25, 2025

The Saturday Spread: Using Data Science to Find Call Spreads Priced in Your Favor

It’s already difficult enough when you step into the world of options. Here’s how to even up the odds against the big dogs.

Barchart · Oct 10, 2025

Here's What to Expect From Amgen’s Next Earnings Report

Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.

Benzinga · Oct 6, 2025

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).

Kiplinger · Oct 2, 2025

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Barchart · Sep 27, 2025

The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback

Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.

Benzinga · Sep 26, 2025

Amgen Expands US Manufacturing Network Amid New Tariff Policy

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Benzinga · Sep 22, 2025

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

1 2 3 4 5

Coverage From

People

Donald Trump

219,898 stories

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.